Products for Research Use Only
RegisterLogin

Fulzerasib

CAT: 0804-HY-152848-02Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-152848-02Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab.[1][2].
CAS Number
2641747-54-6
Product Name Alternative
IBI351; GFH925
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fulzerasib.html
Purity
99.60
Solubility
DMSO : 116.67 mg/mL (ultrasonic)
Smiles
O=C(C=C)N1CCN2C(C3=C(N4C5=C(C(C)C)N=CC=C5C)N=C(C6=C(O)C=CC=C6F)C(Cl)=C3)=C(N(C)C([C@@]2([H])C1)=O)C4=O
Molecular Formula
C32H30ClFN6O4
Molecular Weight
617.07
References & Citations
[1]Rafael Rosell, et al. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC) . Crit Rev Oncol Hematol. 2024 Mar:195:104228.|[2]Vanesa Gregorc, et al. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib. Free access.June 05, 2024
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
K-Ras

Chemical Information

Fulzerasib

Fulzerasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor. Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation). Fulzerasib has a monoisotopic molecular weight of 630.22 Da.

CAS Number2641747-54-6
PubChem CID167713279
IUPAC Name(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-7,9-dimethyl-12-(4-methyl-2-propan-2-yl-3-pyridinyl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione
Molecular FormulaC33H32ClFN6O4
Molecular Weight631.1
XLogP4.1
Topological Polar Surface Area110
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Heavy Atom Count45
Formal Charge0
Complexity1270
SMILES
CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C4=C(C2=O)N(C(=O)[C@@]5(N4CCN(C5)C(=O)C=C)C)C)Cl)C6=C(C=CC=C6F)O
InChI
InChI=1S/C33H32ClFN6O4/c1-7-23(43)39-13-14-40-28-19-15-20(34)26(24-21(35)9-8-10-22(24)42)37-30(19)41(27-18(4)11-12-36-25(27)17(2)3)31(44)29(28)38(6)32(45)33(40,5)16-39/h7-12,15,17,42H,1,13-14,16H2,2-6H3/t33-/m1/s1
InChIKey
BRWVQEWFJJFLIQ-MGBGTMOVSA-N
Chemical Structure
2D Structure
2D structure of Fulzerasib
CAS: 2641747-54-6
CID: 167713279
Formula: C33H32ClFN6O4
MW: 631.1
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight631.1
XLogP34.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass630.2157594
Monoisotopic Mass630.2157594
Topological Polar Surface Area110 Ų
Heavy Atom Count45
Formal Charge0
Complexity1270
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
T73190-01Fulzerasib
A24228-5Fulzerasib (IBI351, GFH925) 5mg
A24228-1Fulzerasib (IBI351, GFH925) 1mg
A24228-50Fulzerasib (IBI351, GFH925) 50mg
A24228-10Fulzerasib (IBI351, GFH925) 10mg

Popular Products